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Introduction: Stage IIIA non-small cell lung cancer (NSCLC)
constitutes a heterogeneous group of patients with predominant
ipsilateral mediastinal (N2) disease. The spectrum of lymph node
presentation has lead to a host of trials involving various therapeutic
combinations, and optimal management has been unclear.
Methods: In 2007 and 2008, 10 live research events surveyed the
practice preferences of American medical oncologists using two
hypothetical scenarios. The first scenario was of a stage IIIA
NSCLC in the right upper lobe with a single enlarged (1 cm) 4R
lymph node found to be malignant by mediastinoscopy. The second
was of a bulky stage IIIA NSCLC with multistation N2 pathologi-
cally positive nodes.
Results: In the first scenario, 373 (92%) of the oncologists incor-
porated surgery into their treatment plan. Only 34 (8%) offered
chemoradiotherapy alone. Neoadjuvant chemotherapy, followed by
surgery and then additional chemoradiotherapy (32%), was the most
commonly offered treatment strategy. In the second scenario, 209
(52%) medical oncologists chose definitive chemoradiation. A total
of 193 (48%) included surgery as part of the treatment plan.
Conclusions: The current standard of care for IIIA N2 NSCLC
recognized before treatment is concurrent chemoradiotherapy. This
study demonstrated that a significant proportion of oncologists
treating locally advanced lung cancer include surgery as part of the
treatment plan more so in single versus multinodal station disease.
Since node positive locally advanced disease is such a common
presentation for patients with lung cancer, well-designed clinical
trials are needed to define the most advantageous treatment strategy
for individual subsets of patients with stage IIIA disease.
Key Words: Non-small cell lung cancer, Bulky 3A disease, Treat-
ment preferences.
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Stage IIIA non-small cell lung cancer (NSCLC) constitutesa heterogeneous group of patients with locally advanced
disease, predominantly to the ipsilateral mediastinal (N2)
lymph nodes, although patients with T3N1 and T4N0-1
disease are also included. The spectrum of N2 nodal presen-
tation extends from resected microscopic N2 nodal metastasis
discovered at the time of surgery to nonresectable bulky
multistation disease. Importantly, an estimated 22% of new
cases diagnosed with NSCLC present with locally advanced
disease representing approximately 49,000 patients annually
with an overall 5-year survival of 24%.1,2
Different therapeutic strategies that include surgery,
chemotherapy, radiotherapy, or some combination of these
modalities have been offered to patients with stage IIIA
NSCLC. The results of clinical trials involving patients with
IIIA disease, coupled with the heterogeneity of disease pre-
sentation within this category, have led to controversies in
how these patients are managed. Thus, the optimal approach
to the management of these patients remains to be defined.1,3
Nevertheless, several guidelines have been formulated in an
attempt to enable physicians to conform their practice to the
best available evidence. There are limited data quantitating
practice preferences of American medical oncologists in
academic and community settings for management of pa-
tient’s with stage IIIA NSCLC. To better answer this ques-
tion, we used two case-based scenarios to study the practice
preferences of medical oncology physicians for treating stage
IIIA N2 NSCLC.
MATERIALS AND METHODS
In 2007 and 2008, the Network for Medical Commu-
nication and Research (NMCR, now Xcenda, Palm Harbor,
FL) conducted 10, lung cancer-related, live research events
involving American medical oncologists and focused in part
on preferred management plans for patients with stage IIIA
N2 NSCLC. Attendees self-selected for participation, regis-
tering via the NMCR Web site. These live events serve as
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anonymous, information-gathering exercises using case-
based scenarios and sensitivity analyses to gain quantitative
insights around current practice preferences and prescribing
plans and the drivers for those preferences of the physician
consultant participants. They are not continuing medical
education events. There is no “introductory lecture” before
the assessment of practice preferences related to any given
case. The participants do have the opportunity to benchmark
their own practice preferences and prescribing plans against
the aggregate selection totals displayed after each question is
answered anonymously using a wireless electronic scoring
system. When the case is completed, there is a brief expert
“level-setting exercise” based on information that has been
acquired and displayed.
The physician participants studied in these research
events were consultants to NMCR, participating under the
auspices of a signed consultant agreement. They were reim-
bursed for meeting expenses, including travel costs and
specific out-of-pocket expenses, from NMCR. Attendees did
not receive honoraria. The research events are not “spon-
sored” by drug companies. Rather, the NMCR analytics
group has research collaborations with certain pharma part-
ners who find value in data generated from repetitive, longi-
tudinal, quantitative assessments of physician-prescribing be-
haviors in selected clinical settings. There is no identification
of any specific pharmaceutical partner during the research
event, nor is there any messaging as part of the short level
setting exercises that occurs after each case scenario has been
presented, and the practice preference and prescribing plan
data have been acquired.
Two hypothetical clinical scenarios and case-based
questions were presented to all participants. The first scenario
(single node disease) was of a stage IIIA NSCLC in the right
upper lobe with a single enlarged (1 cm) 4R lymph node
found to be malignant by mediastinoscopy. The second was
of a bulky (defined as tumor extending within 2 cm of the
main carina with multiple nodes measuring 1.3 to 2.5 cm in
shortest diameter) stage IIIA NSCLC with multistation N2
pathologically positive nodes. Neither scenario had evidence
of metastatic disease or contraindications to surgical inter-
vention. The question and answer options were visually
projected and read aloud by the meeting moderator. There
were four to five response choices for each question. Table 1
shows the scenarios and accompanying questions. After each
individual question was read and answer choices were dis-
played, participants quickly selected a preferred treatment
approach from among the options offered. The results were
tallied and projected in bar graph format before the next
question was displayed. This was followed by expert com-
mentary on the core clinical issue addressed in the question
and an interactive question and answer session.
Associations between treatment selection and various
physician characteristics were assessed using traditional 2
tests and Mantel-Haenszel 2 tests (for ordinal characteris-
tics). For the purposes of the comparisons, treatment selec-
tions were all dichotomized into those that include surgery
and those that did not. Analyses were conducted in SAS v 9.2
(Cary, NC), and any p  0.05 was considered statistically
significant.
RESULTS
A total of 406 oncologists attended five NMCR meet-
ings over the course of 2007. In 2008, 479 oncologists
attended an additional five NMCR meetings, and although
demographics are not available for this group, answer selec-
tions were obtained. The total number of participants in 2007
who chose to contribute to the demographic profile was 381
(Table 2). The majority of the participating oncologists were
males (75%) who practiced in a small group private setting
(62%). They represented oncologists from areas throughout
the contiguous U.S. The majority, 351 (91%), reported treat-
ing less than 10 new lung cancer patients monthly.
When presented with the case of single node disease
(scenario 1), 373 (92%) of the oncologists incorporated
surgery into their treatment plan. Only 34 (8%) offered
chemoradiotherapy alone (Table 3). Neoadjuvant chemother-
TABLE 1. Scenarios and a Sample of a Case-Based
Question Presented
Scenario 1
A 56-yr-old high school biology teacher and avid cyclist notes some
decreased ability to “handle” long weekend bike rides. She sees her
PCP who hears some focal wheezing on chest auscultation prompting a
CXR. There is a noncalcified RUL nodule seen. Follow-up CT scan
shows a 2.6-cm RUL mass with modest hilar enlargement and only one
right paratracheal node with a short diameter 1 cm. The specimen
from a TTNA of the lung lesion is read as adenocarcinoma. A right
cervical mediastinoscopy is positive for a small focus of tumor in one
node from the level 4 R paratracheal region. A PET scan is negative
except in the primary lesion. She is discussed in multidisciplinary
conference.
Scenario 2
The same 56-yr-old high school biology teacher and avid cyclist notes
some decreased ability to “handle” long weekend bike rides. She sees
her PCP who hears some focal wheezing on chest auscultation
prompting a CXR. There is a noncalcified RUL mass seen as well as
some hilar and mediastinal fullness. Follow-up CT scan shows a 4.3-cm
medial RUL mass with suspicious hilar, paratracheal, and subcarinal
node enlargement. The suspicious nodes range from 1.3 to 2.5 cm in
shortest diameter. Bronchoscopy shows tumor involving the right upper
lobe bronchus and extending to within 2 cm of the main carina.
Brushings, a TBB, and a Wang needle aspiration of level 7 nodes are
performed. All show adenocarcinoma. A PET scan is positive in the
primary and the enlarged hilar and mediastinal nodes. She is discussed
in multidisciplinary conference.
Sample question
What would you recommend as your definitive therapy plan?
A. Complete surgical resection followed by adjuvant chemotherapy
B. Complete surgical resection followed by adjuvant chemotherapy and
radiation
(Concurrent or sequential)
C. Induction chemotherapy followed by complete resection 
additional CT and radiation
D. Induction chemo radiotherapy and then complete resection 
additional chemotherapy
E. Concurrent chemo radiotherapy either alone or with induction or
consolidation chemotherapy
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apy, followed by surgery and additional chemoradiotherapy
(32%), was the most commonly offered treatment strategy.
In the case of bulky multistation N2 disease (scenario
2), 209 (52%) medical oncologists chose definitive chemora-
diation. Surprisingly, 193 (48%) included surgery as part of
the treatment plan. Of the group that included surgery, the
most preferred single strategy (67%), was one which used
neoadjuvant chemoradiotherapy followed by surgery and
additional chemoradiotherapy.
Treatment preferences were not influenced by physi-
cian gender, geographical location, practice size, or the num-
ber of lung cancer patients seen monthly. However, surgery
as part of the treatment strategy in patients with bulky disease
was preferred significantly more often by self-reported aca-
demic as opposed to community oncologists (63% versus
44%, p  0.004). Additionally, there was a significant (p 
0.011) association between physician’s years out of training
and treatment selection, with more junior physicians being
more likely to opt for treatments that include surgery (5
years out: 59% prefer surgery; 5–10 years: 47%; 11–20 years:
47%; 20 years: 40%).
The same clinical scenarios and questions were pre-
sented at an additional five meetings in held in the calendar
year 2008. The choices of treatment plan based on scenarios
were strikingly similar to those chosen by the group polled in
the calendar year 2007 (Table 3).
DISCUSSION
This study has several important findings. First, there is
significant variation among medical oncologists in how they
manage IIIA N2 NSCLC. Second, most of patients with
single station N2 disease are offered surgery as part of their
treatment regimen. Finally, surgery is offered to nearly half of
the patients presenting with bulky multistation N2 disease
where there is no evidence for benefit.
The variations in nodal presentation in those with IIIA
N2 disease and the lack of consensus on how to manage them
have presented the clinical trialist with numerous challenges
in generating an optimal clinical design. This has lead to a
host of trials involving various therapeutic combinations that
include surgery and/or chemotherapy and/or radiation therapy
with conflicting results. Many published studies have signif-
icant limitations because they are not randomized, lack rig-
orous pretreatment staging, or involve significant inhomoge-
neity in the study population, making interpretation of the
results difficult. Most investigators would agree that the
standard of care for bulky multistation stage IIIA N2 disease
is concurrent chemoradiotherapy.4–7 The optimal treatment
strategy for single station N2 disease, however, remains
controversial.3,8
The American College of Chest Physicians’ evidence-
based clinical practice guidelines for the treatment of stage
IIIA recommend the following: (1) combination chemoradio-
therapy, especially delivered concurrently, is the preferred
treatment for prospectively recognized stage IIIA lung cancer
with all degrees of mediastinal lymph node involvement; (2)
adjuvant chemotherapy after complete resection of stage IIIA
disease found unexpectedly at the time of surgery; (3) neo-
adjuvant therapy followed by surgery for a known IIIA lung
cancer is not recommended.3 These guidelines were pub-
lished in 2007 after the initial results of the Intergroup trial
0139 were published, but before the complete results were
available in 2009.
TABLE 2. Self-Reported Demographics of Participants,
2007
Gender N  386
Male 291 (75%)
Female 95 (25%)
Years out of training N  381
5 yr 96 (25%)
5–10 77 (20%)
11–20 93 (25%)
20 115 (30%)
Type of practice N  383
Academic 72 (19%)
Community 311 (81%)
Practice size N  382
Solo 92 (25%)
2–5 162 (42%)
6–10 58 (15%)
10 70 (18%)
Geographic location N  381
Northeast 80 (21%)
Southeast 70 (18%)
Central 80 (21%)
Southwest 54 (15%)
West 97 (25%)
Lung cancer patients/mo N  384
5 180 (47%)
5–10 171 (45%)
11–15 21 (5%)
15 12 (3%)
TABLE 3. Comparison of Clinician Choices for Each
Scenario
2007 Treatment Strategy
Scenario 1
N  406
Scenario 2
N  403
Include surgery 372 (92%) 193 (48%)
Surgery  chemo 78 (19%) 8 (2%)
Surgery  chemo XRT 83 (20%) 8 (2%)
NeoC  S  AdjC/XRT 83 (20%) 48 (12%)
NeoC/XRT  S  AdjC/XRT 128 (32%) 129 (32%)
C/XRT  C 34 (8%) 209 (52%)
2008 Treatment strategy
Scenario 1
N  478
Scenario 2
N  479
Include surgery 424 (89%) 257 (54%)
Surgery  chemo 96 (20%) 5 (1%)
Surgery  chemo XRT 86 (18%) 13 (3%)
NeoC  S  AdjC/XRT 93 (19%) 59 (12%)
NeoC/XRT S  AdjC/XRT 149 (31%) 180 (37%)
C/XRT C 54 (11%) 222 (46%)
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Similarly, the most recent NCCN guidelines recom-
mend concurrent chemoradiotherapy for bulky N2 disease. In
contrast to the ACCP guidelines, however, the use of either
surgery with or without radiotherapy for locoregional control
in those with single station N2 disease who respond to
induction chemotherapy are both supported.8
There is controversy in the role of surgical resection
in patients with IIIA N2 disease. Perhaps it is important to
describe the extent of mediastinal disease, the time at
which it is discovered (preoperatively versus intraopera-
tively), and the bulk of disease. There are varying levels of
evidence to support treatment for each of these scenarios.
A patient with incidental or occult N2 disease found
at the time of surgery should be approached differently
than those with N2 disease discovered preoperatively.
Findings by Andre and colleagues suggested a correlation
between the bulk and extent of N2 status and survival.
Patients with low-volume or microscopic mediastinal
nodal involvement were found to have a 5-year survival of
29% when treated with surgery alone versus a 7% 5-year
survival in those with macroscopic N2 metastases treated
in the same way.9 Survival for those with resected micro-
scopic IIIA disease is clearly improved with adjuvant
chemotherapy.10
In those with preoperatively discovered N2 disease,
concurrent chemoradiotherapy is the recommended treat-
ment. In those with single station N2 disease, there is dis-
crepancy between the guidelines about the inclusion of sur-
gery in the treatment plan.
In patients with bulky, multistation N2 disease, combi-
nation chemoradiotherapy is the standard of care.3,8 There is
no evidence that the inclusion of surgery as part of the
treatment strategy in this situation confers additional clinical
benefit; still 48% of participants included it.
Two multicenter randomized trials were performed to
examine the benefit of surgery in stage IIIA, N2 disease.11,12
The European Organization for Research and Treatment of
Cancer (EORTC) completed a large multicenter randomized
trial that compared surgery versus radiotherapy in patients
with stage IIIA disease who showed response to induction
chemotherapy.12 Of the 579 patients who received induction
chemotherapy, 61% demonstrated a response (complete, par-
tial, or minor). One hundred sixty-five patients underwent
surgery, of which 40% had postoperative radiation for incom-
plete resection, while 165 received sequential radiotherapy
without surgery. There was no difference in median (17.5
months versus 16.4 months) or 5-year (14% versus 15.7%)
survival between the nonsurgical and surgical arms, respec-
tively, supporting the guideline conclusion for chemoradio-
therapy as the treatment of choice for unresectable patients
with stage IIIA N2 disease. The study design arguably fa-
vored the surgical arm because the nonsurgical arm received
sequential chemoradiotherapy rather than concurrent treat-
ment which has been shown to improve survival in patients
with locally advanced disease.13
The intergroup trial 0139 randomized 429 patients with
T1–3 biopsy-proven N2 NSCLC and good performance sta-
tus between induction chemoradiotherapy followed by sur-
gery or consolidation with radiotherapy.11 In contrast to the
EORTC trial detailed earlier, most of patients accrued in
either arm had single station nodal disease (76%). Overall
survivorship was similar between the groups (23.6 versus
22.2 months). An unplanned subset analysis separated pa-
tients in the surgical arm who underwent lobectomy and
matched them to patients in the nonsurgical arm based on
age, sex, performance status, and clinical T stage.11 They
could not be paired on the extent and bulk of N2 disease or
response to therapy, perhaps the most important factor asso-
ciated with survival. Although this post hoc analysis showed
an improved survival in those undergoing lobectomy (33.6
months versus 21.7 months, p 0.002), the authors point out
that these findings can only be considered hypothesis gener-
ating and not conclusive.
The differences in overall survival at 5 years between
the two studies (Intergroup 0139 27% versus EORTC 15.7%)
further highlight the selection biases of each study. Those
patients enrolled in the intergroup trial were more likely to
have single N2 disease, whereas those in the EORTC study
were more likely to have multistation N2 disease. This is
admittedly speculative and other differences between the
trials may have affected outcomes.
The differing patient populations, study design, and
nodal status could have contributed to the divergent conclu-
sions engendered by the readers of these two articles. This
may also explain some of the large variation in treatment
practices for stage IIIA N2 NSCLC among U.S. medical
oncologists. Differing interpretations of the carefully worded
recommendations by the ACCP and NCCN guideline panels
may have also contributed to this practice. The ACCP guide-
lines recommend chemoradiotherapy as primary treatment for
patients in preoperatively recognized IIIA N2 disease and
state surgery should not be included outside of a clinical trial.
The NCCN guidelines, conversely, list surgery as an option if
the decision is rendered by a multidisciplinary thoracic on-
cology group after induction chemotherapy or induction che-
moradiotherapy.3,8
Although the treatment of single station N2 disease is
controversial, what is less ambiguous is the therapeutic ap-
proach in patients presenting with multistation N2 disease.
The results for this scenario included surgery in the overall
treatment algorithm by 48 and 54% of the respondents in the
years 2007 and 2008, respectively. Neither of the aforemen-
tioned trials or the guidelines supports the inclusion of sur-
gery for the patient outlined in scenario 2. A possible expla-
nation for this behavior may have been the improved
outcomes in patients reported in two phase II trials published
in 1994 in high-impact journals which demonstrated an in-
creased survival in patients with 3A NSCLC that received
preoperative chemotherapy.14,15 Relatively widely and im-
plicitly assumed is that induction therapy can be used to
render an unresectable patient resectable and that successful
resection will improve overall survival. The above referenced
EORTC trial essentially refutes this. The results of our study
suggest that the findings from the phase II studies along with
the post hoc, unplanned subset analysis performed in Inter-
group 0139 are being inappropriately generalized to the
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population of patients with bulky N2 disease. An alternative
explanation for this practice may be that it is supported by a
significant number of self-reported academic oncologists
(63%). Further, academicians are intimately involved with
the training of fellows which may explain the finding that a
higher proportion of practicing oncologists less than 5 years
out from training were more likely to opt for treatment
strategies that included surgery.
CONCLUSIONS
The current standard of care for IIIA N2 NSCLC
recognized before treatment is concurrent chemoradiother-
apy. This study demonstrated that a significant proportion of
oncologists treating locally advanced lung cancer include
surgery as part of the treatment plan more so in single versus
multinodal station disease. Because node positive locally
advanced disease is such a common presentation for patients
with lung cancer, well-designed clinical trials are needed to
define the most advantageous treatment strategy for individ-
ual subsets of patients with stage IIIA disease to better inform
treatment decisions and guide practicing clinicians.
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